Abstract
The treatment options for synovial sarcoma (SS) are very limited, though this type of sarcoma seems to be more heterogeneous than it has been traditionally considered. The present study investigates the Her-2 oncogene status of 20 cases of SS, to determine whether Her-2 amplification can be considered as a prognostic factor. Her-2 oncogene amplification was determined on smears (frozen material was used from our tumor bank in each case), using fluorescence in situ hybridization technique (dual color FISH with centromeric probe for chromosome 17 and specific probe for Her-2 oncogene). Moreover, protein expression was assessed by immunohistochemistry, and DNA ploidy status was measured using image analysis. We had 5 biphasic and 15 monophasic SSs, patients’ age ranged from 13 to 68 years (mean, 39.8 years). Tumor size was larger than 5 cm in each case. Followup time ranged from 6 to 78 months (mean, 38.5 months). For statistical analysis the chi-square test was used. Her-2 oncogene amplification was found in three cases (15.0%) of 20 SSs. These cases proved to be 2+ positive by immunohistochemistry, but massive amplification, characteristic of a subset of breast carcinomas, was not observed. Her-2 oncogene amplification was significantly associated with a lower risk of developing metastasis (P<0.05) (none of the 3 amplified cases had metastases), while no association was found with recurrence. Six cases proved to be aneuploid and 14 were diploid, but no association was found between Her-2 amplification status and ploidy, and between ploidy status and metastasis or recurrence. Our results emphasize and confirm that Her-2 oncogene amplification is a rare event in SS, but the small subset of SS with Her-2 amplification has a better overall prognosis. Furthermore, this may open a theoretically new treatment possibility with Trastuzumab for Her-2-amplified cases of SS.
Similar content being viewed by others
References
Bergh P, Meis-Kindblom, JM, Gherlinzoni F, et al: Synovial sarcoma: identification of low and high risk groups. Cancer 85: 2596–2607, 1999
Lewis JJ, Antonescu CR, Leung DHY, et al: Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol 18: 2087–2094, 2000
Spillane AJ, Ahern R, Judson IR, et al: Synovial sarcoma: a clinicopathologic, staging and prognostic assessment. J Clin Oncol 18: 3794–3803, 2000
Spurrell EL, Fisher C, Thomas JM, et al: Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol 16: 437–444, 2005
Panagopoulos I, Mertens F, Isakesson M, et al: Clinical impact of molecular and cytogenetic findings in synovial sarcoma. Genes Chromosomes Cancer 31: 362–372, 2001
Haroske G, Baak JPA, Danielsen H, et al: Fourth updated ESACP consensus report on diagnostic DNA image cytometry. Anal Cell Pathol 23: 89–95, 2001
Kindermann D, Hilgers CH: Glare-correction in DNA image cytometry. Anal Cell Pathol 6: 165–180, 1994
Barbashina V, Benevenia J, Aviv H, et al: Oncoproteins and proliferation markers in synovial sarcomas: a clinicopathologic study of 19 cases. J Cancer Res Clin Oncol 128: 610–616, 2002
Allander SV, Illei PB, Chen Y, et al: Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 161: 1587–1595, 2002
Thomas DG, Giordano TJ, Sanders D, et al: Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer 103: 830–838, 2005
Nuciforo PG, Pellegrini C, Fasani R, et al: Molecular and immunohistochemical analysis of HER-2/neu oncogene in synovial sarcoma. Hum Pathol 34: 639–645, 2003
Coombs LM, Pigott DA, Sweeney E, et al: Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 63: 601–608, 1991
Kay EW, Mulcaby H, Walsh CB, et al: Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes’ B colorectal carcinoma. Histopathology 25: 455–461, 1996
Keshgegian AA, Cnaan A: erbB-2 oncoprotein expression in breast carcinoma, poor prognosis associated with high degree of cytoplasmic positivity using CB-11 antibody. Am J Clin Pathol 108: 456–463, 1997
Roychowdhury DF, Tseng A Jr,Fu KK, et al: New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and c-erbB-2 expression. Cancer 77: 1419–1426, 1994
Kilpatrick SE, Geisinger KR, King TS, et al: Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol 14: 1277–1283, 2001
Sugg SL, Ezzat S, Zheng L, et al: Cytoplasmic staining of erbB-2 but not mRNA levels correlates with differentiation in human thyroid neoplasia. Clin Endocrinol 49: 629–637, 1998
El-Naggar AK, Ayala AG, Abdul-Karim FW, et al: Synovial sarcoma. A DNA flow cytometric study. Cancer 65: 2295–2300, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sápi, Z., Pápai, Z., Hruska, A. et al. Her-2 oncogene amplification, chromosome 17 and DNA ploidy status in synovial sarcoma. Pathol. Oncol. Res. 11, 133–138 (2005). https://doi.org/10.1007/BF02893389
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02893389